Cancer Research Technology
Log in Register
Menu

CAN I DEPOSIT OR ACCESS RESEARCH TOOLS THAT CONTAIN CRISPR-Cas9 TECHNOLOGY?

Deposit

If you have developed modified cell lines using CRISPR-Cas9 please get in touch.

Access

Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed below.  This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.

ERS Genomics Ltd holds an exclusive worldwide license from Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR-Cas9 for all applications other than use as a human therapeutic. The patent rights belonging to ERS Genomics Ltd are listed below. These patent applications have broad and dominant claims covering CRISPR-Cas9 compositions and methods of genome editing in any organism. 

Click here to view ERS Genomics Ltd Granted Patents


Was this information useful? 36 14

see all FAQ's from this category >